DFDA

Eluxadoline

Treatment for Irritable Bowel Syndrome

Typical Dosage: 100 mg orally twice daily (or 75 mg twice daily for certain patients)

Effectiveness
62%
Safety Score
60%
Clinical Trials
7
Participants
6K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
100 mg orally twice daily (or 75 mg twice daily for certain patients)
Time to Effect
1-2 weeks
Treatment Duration
Long-term (chronic)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
333(Treat 333 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$300
Side Effect Mgmt:$300
Total Annual:$15,600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$110,000/QALY
QALYs Gained
0.06
Outcome-Based Costs
Cost per Responder
$62,400
Cost per Remission
$195,000
Eluxadoline Outcomes

for Irritable Bowel Syndrome

Efficacy Outcomes
Overall Effectiveness
+62%
Response Rate
+25%
Remission Rate
+8%
Common Side Effects
Constipation
+8%
Nausea
+7%
Abdominal pain
+6%
Pancreatitis
+0.3%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Eluxadoline in Irritable Bowel Syndrome

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT04880876ENROLLING BY INVITATIONPHASE3
View Study
124 participants
INTERVENTIONAL
Corona, United States +5 more
Started: Aug 13, 2021

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

NCT03339128RECRUITINGPHASE2
View Study
95 participants
INTERVENTIONAL
Hot Springs, United States +45 more
Started: Nov 15, 2017
Completed Clinical Trials
5 completed trials for Eluxadoline in Irritable Bowel Syndrome

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553747COMPLETEDPHASE3
View Study
1.15K participants
INTERVENTIONAL
Birmingham, United States +252 more
Started: May 29, 2012

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT01130272COMPLETEDPHASE2
View Study
807 participants
INTERVENTIONAL
Anniston, United States +287 more
Started: Apr 28, 2010

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553591COMPLETEDPHASE3
View Study
1.28K participants
INTERVENTIONAL
Athens, United States +282 more
Started: May 29, 2012

Eluxadoline Bile Acid Malabsorption (BAM) Study

NCT03441581COMPLETEDPHASE4
View Study
24 participants
INTERVENTIONAL
Rochester, United States
Started: Feb 23, 2018

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

NCT02959983COMPLETEDPHASE4
View Study
346 participants
INTERVENTIONAL
Huntsville, United States +82 more
Started: Oct 25, 2016